Early treatment with a chemotherapy drug extends the lives of patients with advanced prostate cancer by nearly two years, a major study shows. Docetaxel is normally given after hormone treatment has failed. But results, to be presented at the American Society of Clinical Oncology, will show earlier treatment can extend life expectancy from 43 to
Clinical Research Services in Oncology
- info@oncrodex.co.uk
- 01844 347 305